Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310
A 15-participant phase 1a study reported sustained lipid reductions one year after a single infusion.
TL;DR
- The phase 1a study evaluated a one-time CTX310 infusion in people with lipid disorders.
- At the highest dose, the study reported 52.5% lower LDL cholesterol and 47.8% lower triglycerides from baseline at 12 months.
- The small early-stage trial reports biomarker changes and one year of follow-up; it does not establish long-term clinical outcomes.
The New England Journal of Medicine report describes a phase 1a trial of CRISPR-Cas9 editing targeting ANGPTL3. Cleveland Clinic says the trial included 15 patients and assessed whether earlier lipid reductions persisted through 12 months. [1] [2]
At the highest dose, the report gives reductions from baseline of 52.5% for LDL cholesterol and 47.8% for triglycerides after one year. The study was supported by CRISPR Therapeutics. [1] [2]
This is early-stage evidence from a small study with one year of follow-up. The sources do not report whether the observed lipid changes reduce cardiovascular events over longer periods. [1] [2]
Why it matters
The result is a clinical-stage test of durable in-vivo gene editing, with implications for biotech development while long-term outcomes remain unknown.
Editor's note
No medical recommendation is implied; report results as trial findings and preserve the phase 1a and sample-size context.